and 5-HT 1A agonist. The randomized, double-blind, placebo-controlled, parallel-group phase 3 FOCUS trial (ClinicalTrials.gov Identifier: NCT05972044) evaluated the efficacy and safety of ...

HoYoverse recently shared the event schedule for the first phase of version 5.5. The event-exclusive 5 ... Resin to claim double rewards up to three times per day. Players need to be Adventure ...